State‐of‐the‐art 2023 on gene therapy for phenylketonuria
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12651 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Michael Martinez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Phenylalanine Hydroxylase, Phenylketonurias. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, NIH HHS, Swiss National Science Foundation.
Abstract (Originalsprache)
Phenylketonuria (PKU) or hyperphenylalaninemia is considered a paradigm for an inherited (metabolic) liver defect and is, based on murine models that replicate all human pathology, an exemplar model for experimental studies on liver gene therapy. Variants in the PAH gene that lead to hyperphenylalaninemia are never fatal (although devastating if untreated), newborn screening has been available for two generations, and dietary treatment has been considered for a long time as therapeutic and satisfactory. However, significant shortcomings of contemporary dietary treatment of PKU remain. A long list of various gene therapeutic experimental approaches using the classical model for human PKU, the homozygous enu2/2 mouse, witnesses the value of this model to develop treatment for a genetic liver defect. The list of experiments for proof of principle includes recombinant viral (AdV, AAV, and LV) and non‐viral (naked DNA or LNP‐mRNA) vector delivery methods, combined with gene addition, genome, gene or base editing, and gene insertion or replacement. In addition, a list of current and planned clinical trials for PKU gene therapy is included. This review summarizes, compares, and evaluates the various approaches for the sake of scientific understanding and efficacy testing that may eventually pave the way for safe and efficient human application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
- Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
- Division of Metabolism, University Children's Hospital Zurich and Children's Research Centre, Zurich, Switzerland.
ORCID-Profile: Beat Thöny
Förderung
- NICHD NIH HHS
- NIH HHS
- Swiss National Science Foundation
- National PKU Alliance
- National Institutes of Health
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Martinez, M., Harding, C. O., Schwank, G., & Thöny, B. (2024). State‐of‐the‐art 2023 on gene therapy for phenylketonuria. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12651
Vancouver
Martinez M, Harding CO, Schwank G, Thöny B. State‐of‐the‐art 2023 on gene therapy for phenylketonuria. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12651
BibTeX
@article{Martinez2024,
author = {Martinez, Michael and Harding, Cary O and Schwank, Gerald and Thöny, Beat},
title = {State‐of‐the‐art 2023 on gene therapy for phenylketonuria},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12651}
}
EUVIMED